Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 4/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31438692 | 1.00 | DHODH (0.41) | DHODHNPC1RAB9ATRPV1F10 | |
| SCHEMBL29416624 | 0.89 | IDO1 (0.38) | DHODHNPC1RAB9AIDO1NAMPT | |
| SCHEMBL196132 | 0.89 | IDO1 (0.38) | DHODHNPC1RAB9AIDO1NAMPT | |
| SCHEMBL590485 | 0.88 | TRPV1 (0.42) | NPC1RAB9ATRPV1F10IDO1 | |
| SCHEMBL29355401 | 0.88 | IDO1 (0.38) | DHODHNPC1RAB9AIDO1NAMPT | |
| SCHEMBL27174182 | 0.88 | IDO1 (0.38) | DHODHNPC1RAB9AIDO1NAMPT | |
| SCHEMBL29416636 | 0.88 | IDO1 (0.38) | DHODHNPC1RAB9AIDO1NAMPT | |
| SCHEMBL230723 | 0.88 | IDO1 (0.38) | DHODHNPC1RAB9AIDO1NAMPT | |
| SCHEMBL29416550 | 0.87 | DHODH (0.40) | DHODHNPC1RAB9AIDO1NAMPT | |
| SCHEMBL195314 | 0.87 | DHODH (0.40) | DHODHNPC1RAB9AIDO1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2093223-B1 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-8481744-B2 | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2013-07-09 | — | — | US | disclosed |
| EP-2264021-B1 | PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-8115006-B2 | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110034696-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264021-A1 | PROCESS FOR PRODUCING AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA ,LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2093223-A1 | PROCESS FOR PRODUCTION OF ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | NAAA, AAAS, AADAC | DHODH 927/4885NPC1 4477/4885RAB9A 146/4885 |
| US-20110034696-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | SQOR, NOX5, NOX3 | DHODH 149/4885NPC1 4819/4885RAB9A 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.